| Date | Title | Description |
| 24.02.2026 | Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate | Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infections
Investment from the world’s largest venture capital fund focused exclusively on a... |
| 12.01.2026 | Locus Biosciences Receives $3.3M Award From NIH | Locus Biosciences, a Morrisville, NC-based clinical-stage biotechnology company, received a $3.3M award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
The awarded con... |
| 18.10.2025 | Peptilogics Secures $78M to Advance Breakthrough PJI Therapy Zaloganan | Peptilogics, a clinical-stage biotechnology firm, closed an oversubscribed $78 million Series B2 funding round. This capital propels zaloganan (PLG0206), its lead candidate, toward a pivotal Phase 2/3 clinical trial. Zaloganan targets prost... |
| 16.10.2025 | Peptilogics: $78 Million Raised For Advancing Zaloganan Toward Pivotal Trial For Prosthetic Joint Infections | Peptilogics, a clinical-stage biotechnology company pioneering surgical therapeutics for medical device infections, has closed an oversubscribed $78 million Series B2 financing round. The funding round was led by Presight Capital, Thiel Bio... |
| 16.10.2025 | Peptilogics Raises $78M in Series B2 Funding | Peptilogics, a Pittsburgh, PA-based clinical-stage biotechnology company developing surgical therapeutics to effectively treat and prevent serious medical device infections, closed a $78m Series B2 financing round.
Presight Capital, Thiel B... |
| 25.08.2025 | Baxiva secures USD 3M to advance antibacterial vaccines | Escherichia coli is the leading cause of urinary tract infections, a frequent cause of neonatal sepsis, and a major contributor to antimicrobial resistance-related deaths worldwide. Baxiva's approach focuses on multivalent vaccines, which a... |
| 22.08.2025 | Baxiva secures $3 million to advance antibacterial vaccines |
Escherichia coli (E. coli) is the leading cause of urinary tract infections, a frequent cause of neonatal sepsis, and is among the leading causes of antimicrobial resistance-associated deaths globally. One approach to tackle this is with m... |
| 08.08.2025 | SNIPR BIOME Secures €35 Million to Revolutionize CRISPR-Medicine | Copenhagen's SNIPR BIOME clinched €35 million in Series B funding. This significant capital injection drives microbial CRISPR-medicine innovation. Funds target critical health challenges: developing CRISPR-Cas therapy for severe airway infe... |
| 08.08.2025 | Danish BioTech scale-up SNIPR Biome raises €35 million to target antimicrobial resistance in diseases like cancer | Copenhagen-based SNIPR Biome, a BioTech company innovating the development of microbial CRISPR-medicine, announced the close of a €35 million Series B raise to advance CRISPR-based therapies for cystic fibrosis airway infections, combat ant... |
| 07.08.2025 | Centauri Therapeutics: $5.1 Million Raised From CARB-X | Centauri Therapeutics, an immunotherapy company, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has granted an additional $5.1 million to support the development of its lead compound. Thi... |
| 07.08.2025 | SNIPR BIOME Raises EUR 35M in Series B Funding | SNIPR BIOME, a Copenhagen, Denmark-based company improving the development of microbial CRISPR-medicine, raised EUR 35M in Series B funding.
Backers included Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovati... |
| 30.07.2025 | Centauri Secures $5.1M CARB-X Boost for Lifesaving Antimicrobial Trials | Centauri Therapeutics secured $5.1 million from CARB-X, pushing its ABX-01 program towards human trials. Total CARB-X support now reaches $12.3 million. This crucial investment drives ABX-01, an Alphamer-based broad-spectrum antimicrobial, ... |
| 29.07.2025 | Centauri gets $5.1M from CARB-X to advance ABX-01 to human trials | UK-based Centauri Therapeutics, an immunotherapy company with a proprietary platform technology applicable across a wide range of therapeutic areas, has secured an additional $5.1 million in funding from CARB-X. This brings CARB-X’s total s... |
| 29.07.2025 | Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials | CARB-X provides an additional $5.1M to complete the non-clinical safety and efficacy studies with ABX-01 lead candidate
Centauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in hum... |
| 29.07.2025 | Kinvard Bio Receives Follow-on CARB-X Funding | Kinvard Bio Inc., a Raleigh, NC-based biotechnology company providing a new class of broad-spectrum antibiotics, received US$2.7M follow-on non-dilutive funding from CARB-X.
The company intends to use the funds to accelerate the advancement... |
| 17.02.2025 | LimmaTech secures US$6.5 million to advance vaccine against S. aureus |
LBT-SA7 is designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen Staphylococcus aureus (S. aureus). S. aureus infections pose a significant global health challenge, causing an estimated 1 million deat... |
| 22.12.2024 | GangaGen Secures additional US$7.9 Million from CARB-X for Pre-clinical Development of Novel Klebicins Targeting Nosocomial Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae | BANGALORE, INDIA / SINGAPORE – Media OutReach Newswire – 23 December 2024 – GangaGen announced today that it has secured the third instalment of its phased funding grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical... |
| 01.03.2024 | A wave of success for LimmaTech |
LimmaTech is a clinical stage biotech company that has built a robust pipeline of innovative vaccines using their proprietary self-adjuvanting and multi-antigen vaccine technology platform. The startup was awarded $2.2 million from the Com... |
| 24.10.2022 |
Day Zero Diagnostics raises $8.2M from CARB-X | Day Zero Diagnostics announced that it received an $8.2 million award in optional stage funding from CARB-X.
The infectious disease diagnostic developer received an initial $6.2 million CARB-X award in May 2020. CARB-X, the Combating Antibi... |
| 15.07.2022 | As Big Pharma loses interest in new antibiotics, infections are only growing stronger | Forget Covid-19, monkeypox, and other viruses for the moment and consider another threat troubling infectious disease specialists: common urinary tract infections, or UTIs, that lead to emergency room visits and even h... |
| 20.04.2022 | SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001 | SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
Wed, Apr 20, 2022 07:00 CET Report this content
Copenhagen, April 20th, 2022: SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, today annou... |
| 25.01.2022 | SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients. | SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients. Tue, Jan 25, 2022 14:54 CET
Copenhagen, January 25th, 2022: SNIPR BIO... |
| 11.01.2022 | SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections | SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections Tue, Jan 11, 2022 07:00 CET
Copenhagen, January 11th, 2022: SNIPR BIOME ApS... |
| 19.10.2021 | CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections | LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its an... |
| 11.08.2021 | Seattle startup Lumen Bioscience is working with Google to make drugs using algae | Caitlin Gamble, head of informatics at Lumen Bioscience. (Lumen Photo)
Can machine learning help spur the production of algae-based biologics? That’s the question new research from Seattle biotech startup Lumen Bioscience and Google aims to... |
| 05.08.2021 | Vaxcyte : Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections | -- Award Commits an Additional $3.2 Million in Funding; Total Potential Funding of $29.7 Million Based on Future Milestones --
-- Vaxcyte Plans to Initiate IND-Enabling Studies for VAX-A1 in Second Half of 2021 --
FOSTER CITY, Calif., Aug. ... |
| 15.07.2021 | Seattle startup Lumen Bioscience to build algae manufacturing plant in former bakery | Former bakery and future algae manufacturing site. (GeekWire Photo / Charlotte Schubert)
Seattle-based biotech company Lumen Bioscience, which manufactures proteins in algae, will expand its manufacturing operations to a former bakery in th... |
| 15.07.2021 | Seattle startup Lumen Biosciences to build algae manufacturing plant in former bakery | Former bakery and future algae manufacturing site. (GeekWire Photo / Charlotte Schubert)
Seattle-based biotech company Lumen Bioscience, which manufactures proteins in algae, will expand its manufacturing operations to a former bakery in th... |
| 09.06.2021 | ACCELERATE DIAGNOSTICS, INC.
Accelerate Diagnostics : Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections | Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections
Jun 08, 2021
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global no... |
| 01.06.2021 | BioVersys secures additional funding | |
| 01.06.2021 | BioVersys gets up to USD 15.34 million CARB-X grant to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics | BioVersys gets up to USD 15.34 million CARB-X grant to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics 01.06.2021 09:00, Guillaume Tinsel linkedIn facebook twitter instagram youtube -->
TOP 100 Swiss Startup... |
| 01.06.2021 | BioVersys secures additional funding | BioVersys AG is a multi-asset Swiss pharmaceutical company focusing on developing small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. The compa... |
| 01.06.2021 | BioVersys gets up to USD 15.34 million CARB-X grant to further develop pyrrolocytosines, a novel class of broad-spectrum antibiotics | BioVersys AG, a privately owned clinical-stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR... |
| 18.05.2021 | SUMMIT THERAPEUTICS INC.
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a... | Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in the fight against multidrug resistant infections, specifically... |
| 03.02.2021 | Mutabilis receives CARB-X grant for 'nightmare bacteria' treatment; AbSci and Xyphos shake hands on discovery deal | On a mission to subdue the rising global threat of antibiotic resistance, the CARB-X initiative has inked yet another grant — this one for a French pharma working on a treatment for so-called “nightmare bacteria.”
Romain... |
| 11.01.2021 | Can we warp-speed antibiotic development? | Now, advocates, industry leaders and legislators have come to a consensus about the scope and urgency of the crisis. They have been working together to address it under wide-ranging federal guidance issued in March 2015, titled the “U.S. Na... |
| 14.10.2020 | CARB-X is funding Polyphor to develop a new antibiotic | This is the second antibiotic program under development by Polyphor to win funding and support from CARB-X, a global non-profit partnership led by Boston University dedicated to accelerate the development of new therapeutics, preventatives ... |
| 14.10.2020 | CARB-X is funding Polyphor to develop a new antibiotic | |
| 04.08.2020 | Could Drug-Resistant Bacteria Cause The Next Pandemic? | Venetians dressed as plague doctors pose during Carnival in their city's Piazza San Marco on ... [+] February 25, 2020. Their costume dates to the Italian Plague of 1629–1631. (Photo by Giacomo Cosua/NurPhoto via Getty Images)NurPhoto via G... |
| 17.06.2020 | Module Innovations receives funding worth $702,000 from CARB-X | The funds will be used to develop tests to diagnose UTI and identify superbugs causing the infection within two hours
Pune-based Module Innovations received funding of up to $702,000 from Boston based CARB-X, plus up to $2.5 million more if... |
| 23.04.2020 | Bugworks Raises $7.5 Million | Bugworks Research Inc, a global biopharma start-up designing novel broad-spectrum antibiotics, announced the completion of a $7.5M financing, led by University of Tokyo Edge Capital (UTEC) Japan and Global Brain Corporation (Global Brain) J... |
| 01.04.2020 | VC funding update: 60 startups raised over $1.5B in March | Boston startups ended the first quarter of 2020 with a bang. The disruption caused by COVID-19, the respiratory disease caused by the novel coronavirus, notwithstanding, 60 Beantown startups raised over $1.5 billion.
Chief among those were ... |
| 04.02.2020 | Austin Biotech Startup Looks to Double Its Team After Raising $13M | Everyone knows the saying "time is money." But in hospitals time is worth even more.
Austin biotech startup Pattern Bioscience is tightly focused on saving physicians time as it develops its early-stage bacterial culture testing t... |
| 02.01.2020 | French biotech startup Antabio receives $4.4 million from CARB-X to further development of new treatment for cystic fibrosis patients | Antabion, a Labege, France-based biotech startup announced today it has been awarded up to $4.4 million in a second tranche funding from CARB-X, a global non-profit partnership dedicated to tackling the global rising threat of drug-resistan... |
| 29.10.2019 | BioVersys obtains new funds for its fight against drug-resistant bacteria | |
| 29.10.2019 | Dupixent cleared for chronic rhinosinusitis in EU; FDA grants RMAT status to CARsgen's CAR-T | → Regeneron and Sanofi‘s Dupixent — a king in the eczema therapy sector — has cinched its third type 2 inflammatory disease approval in the EU. On top of severe asthma and moderate-to-severe atopic dermatitis, the drug ca... |
| 19.06.2019 | Oxford Drug Design receives over £8m in grant and equity investment | Oxford Drug Design receives over £8m in grant and equity investment
19-06-2019
Oxford Drug Design (ODD) wins major funding awards from CARB-X, the UK Department of Health and Social Care (DHSC) and an equity investment led by o2h Ventures t... |
| 19.06.2019 | Oxford Drug Design receives over £8m in grant and equity investment | Oxford Drug Design (ODD) wins major funding awards from CARB-X, the UK Department of Health and Social Care (DHSC) and an equity investment led by o2h Ventures totaling over £8m to develop new antibiotics effective against drug-resistant su... |
| 17.04.2019 | Medicare payment rules hinder the fight against superbugs | Late last year, a retirement community in Vermont was quarantined after an outbreak of antibiotic resistant bacteria swept through the facility, sickening 70 seniors. In pediatric oncology wards, children beating cancer are increasingly fel... |
| 04.03.2019 | ContraFect Announces $6.94M In Funding From CARB-X | YONKERS, N.Y., March 04, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistan... |
| 17.01.2019 | ContraFect Announces Additional $2.3M In Funding From CARB-X | YONKERS, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant... |
| 10.12.2018 | What’s holding pharma back from the next antibiotic breakthrough? | In the five years since the alarm sounded about so-called superbugs, the world has continued to grapple with the staggering health and economic impacts of antibiotic resistance and mounting resistance to antibiotics of last resort.
In the U... |
| 25.09.2018 | Researchers point to R&D treaty to spur new infectious disease treatments | As current incentives to promote the development of new infectious disease treatments have yet to reach their potential, researchers in a new Food and Drug Law Journal paper suggest forming a research and development t... |
| 19.07.2018 | Pharmaceutical companies are backing away from a growing threat that could kill 10 million people a year by 2050 | CDC
A researcher tests bacteria's ability to growth in the presence of antibiotics.
Advertisement
Novartis in July became the latest pharmaceutical company to shut down its antibiotics research projects.
The move comes as FDA commissioner S... |
| 07.05.2018 | Allergan aesthetics chief David Moatazedi becomes CEO of Evolus; CARB-X invests $6.2M into Melinta's next-gen antibiotics | David Moatazedi
→ Allergan aesthetics chief David Moatazedi is leaving to take the helm of Evolus, a much smaller biotech developing a rival to Botox. Evolus’ new drug DWP-450 (PrabotulinumtoxinA) is under review. Moata... |
| 11.04.2018 | Innovative ways to pay for new antibiotics will help fight superbugs | Antibiotics are the most important drug class in human history. Without them, minor infections like strep throat or urinary tract infections could turn deadly. Heart surgery, cancer treatment, and virtually everything else that happens in a... |
| 31.03.2017 | A new antibiotic initiative gets its first major round of funding | A budding transatlantic initiative devoted to developing new antibiotics is investing up to $48 million over the next three years in nearly a dozen small companies that are working on what could become the first new class of treatment in de... |
| 31.03.2017 | Promentis raises $26M for glutamatergic drug R&D; CARB-X offers up to $48M for fighting drug-resistant bacteria | → Milwaukee-based Promentis Pharmaceuticals has raised $26 million in a C round. OrbiMed, F-Prime Capital Partners (formerly Fidelity Biosciences) and Aisling Capital led the round. Existing investors, including Bl... |
| - | Can we warp-speed antibiotic development? | While doctors scramble to understand the viral illness Covid-19, bacteria pose no small threat, especially given increasing antibiotic resistance and prevalence of superbugs.
Medical centers rely on antibiotics to treat everything from post... |
